GILEAD SCIENCES SL

🇪🇸Spain

Country: 🇪🇸Spain

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $95.8B

Website: http://www.gilead.com/about/worldwide-operations/europe/spain

Clinical Trials

Avenzo, Gilead partner for breast cancer combination regimen trial

Avenzo Therapeutics and Gilead Sciences partner to assess a combination treatment regimen of AVZO-021 (CDK2 inhibitor) and Trodelvy (Trop-2 ADC) for HR+, HER2- breast cancer. Gilead supplies Trodelvy, while Avenzo conducts and sponsors the study, maintaining all rights for their assets.

Home Terms & Conditions Privacy Policy